Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.445 AUD | +5.95% | +25.35% | +28.99% |
04-24 | Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck | MT |
04-24 | Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B | CI |
Sales 2024 * | 3.19M 2.09M 2.86M | Sales 2025 * | 17.82M 11.68M 15.97M | Capitalization | 529M 347M 474M |
---|---|---|---|---|---|
Net income 2024 * | -44M -28.84M -39.43M | Net income 2025 * | -42M -27.53M -37.64M | EV / Sales 2024 * | 142 x |
Net cash position 2024 * | 75.11M 49.23M 67.31M | Net cash position 2025 * | 61.67M 40.42M 55.27M | EV / Sales 2025 * | 26.2 x |
P/E ratio 2024 * |
-11.7
x | P/E ratio 2025 * |
-12.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.19% |
1 day | +5.95% | ||
1 week | +25.35% | ||
Current month | +17.11% | ||
1 month | +17.11% | ||
3 months | +34.85% | ||
6 months | +41.27% | ||
Current year | +28.99% |
Managers | Title | Age | Since |
---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
David Fang
DFI | Director of Finance/CFO | - | 18-02-28 |
Florian Vogl
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Russell Howard
CHM | Chairman | 74 | 13-05-07 |
Marc Voigt
CEO | Chief Executive Officer | 51 | 10-12-31 |
Anne Anderson
BRD | Director/Board Member | - | 02-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 0.445 | +5.95% | 2,651,345 |
24-04-26 | 0.42 | -6.67% | 4,968,700 |
24-04-24 | 0.45 | +16.88% | 13,371,270 |
24-04-23 | 0.385 | +8.45% | 1,433,061 |
Delayed Quote Australian S.E., April 29, 2024 at 02:10 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+28.99% | 326M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- IMM Stock